~~<i id='2983EA4464'><strike id='2983EA4464'><tt id='2983EA4464'><pre id='2983EA4464'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：fashion 2025-08-23 08:57:00 - browse：8182

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

Wikipedia

entertainment

focus

Wikipedia

leisure time

LungcancerAdobeCHICAGO—DelfiDiagnostics,acompanyseekingtodevelopliquidbiopsyteststohelpscreenforlung

WSS

Obesity drugs seen as possible treatment for liver disease MASH

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Congress needs to close a vaccine

FDA approves Moderna’s RSV vaccine, its second licensed product

STAT wants to know your pick for a great summer read or listen

hotspot

entertainment

Wikipedia

Activists slam private health insurers over coverage restrictions

Data don't support strong claims for Covid

Peter Hotez and the public health issue of online harassment

Alabama hospital puts IVF treatments on hold

Apple is now the first public company to be valued at $3 trillion

With competition flaring, obesity drug hits goal in liver disease study

The cancer drug shortage isn’t new — and neither are the solutions

New documents shed light on MD Anderson Cancer Institute feud

Psychedelics group wrestles with new pharma identity

A new nitrogen execution bill also undermines medical licensing

entertainment

New documents shed light on MD Anderson Cancer Institute feud

A solution to the after

STAT readers on older presidents, polypills, Medicare, and more

The most pressing bird flu mysteries scientists want answered

He's a Nobel laureate. Critics say he was misleading on Covid

Alabama hospital puts IVF treatments on hold

entertainment

focus

Wikipedia

leisure time